Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line. Source: BioSpace

Dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70% on average. Source: BioSpace

Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease. Source: BioSpace

Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe. Source: BioSpace

Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace

Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen. Source: BioSpace

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint. Source: BioSpace

The money is intended to to fuel European biotech startups. Source: BioSpace

Anders Gotzsche will serve as interim CEO while the company looks for a replacement for Kare Schultz who leaves the company Oct. 31 for the CEO position at Teva. Source:…